Live symbol workspace

NVS market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $154.03

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$146.33

Resistance

$161.73

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$154.03

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

— 0.0 pts vs previous week

Avg confidence across 12 calls in the last 7 days

What sources say

No news-sourced AI calls in the last 30 days.

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

NVS News Intelligence (3 articles)

AI-curated news influencing NVS price, sentiment, and trend

Explore All NVS News with AI Analysis

Economy

2 months, 3 weeks ago

Better Pharma Dividend Stock: Novartis vs. Merck

Both are great stocks to buy in the current environment, but which one is the better bet?

Impact on NVS: The comparison between Novartis (NVS) and Merck (MRK) may lead to sector …

The article compares Novartis and Merck as dividend stocks in the pharmaceutical sector, considering their … Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Stocks

3 months ago

Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy …

Impact on NVS: Soleno Therapeutics' stock is soaring in premarket trading, with potential for a …

Neurocrine's potential acquisition of Soleno Therapeutics is driving a surge in Soleno's stock price, with … High (80%)

View full analysis →

MarketWatch 80% confidence

Economy

3 months, 3 weeks ago

SNB Is About to Reveal Its Resolve on Franc Strength

The Swiss National Bank’s determination to cap gains in the franc will draw the spotlight in a decision that is …

Impact on NVS: A strong stance by the SNB to cap franc gains may lead …

The Swiss National Bank (SNB) is set to announce its decision on capping gains in … High (70%)

View full analysis →

Bloomberg 70% confidence